Amneal to Report Third Quarter 2026 Results on November 3, 2026
Amneal Pharmaceuticals (NASDAQ: AMRX) will report third quarter 2026 financial results on November 3, 2026, before market open.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Amneal Pharmaceuticals (NASDAQ: AMRX) will report third quarter 2026 financial results on November 3, 2026, before market open.
An audio webcast will begin at 8:30 a.m. ET. Results and the live webcast will be available at investors.amneal.com, with a webcast replay available shortly after the call.
Details
Market Reaction – AMRX
On Oct 8, the day this news came out, the latest delayed price for AMRX is 0.05% below the previous close. Our momentum scanner has recorded 2 alerts for this stock so far that day. The latest delayed price is $19.64.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Results reporting date
- November 3, 2026
- Third quarter 2026 financial results, before market open
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced it will report third quarter 2026 financial results on Tuesday, November 3, 2026, before market open. The Company will host an audio webcast at 8:30 a.m. ET.
The financial results and live webcast will be available through the Investor Relations section of the Company's website at investors.amneal.com. Individuals may register for the webcast by clicking here. To access the call by phone, dial 1 (833) 461-5787 (U.S.) or view a list of toll-free international numbers here. The access code is 304152835. A replay of the webcast will be available shortly after the call.
About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Amneal was founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, and built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For more information, visit and follow us on LinkedIn.
Investor Contact
Anthony DiMeo
VP, Investor Relations
anthony.dimeo@amneal.com
